Work

Studies of CD44 Hyaluronan Binding Domain as Novel Angiogenesis Inhibitor. CD44 hüaluroonhapet siduv domään kui uudne angiogeneesi inhibiitor

Year: 2013
Type: article
Abstract: hyaluronan, hyaluronic acid HABD, hyaluronan binding domain HIF1α, hypoxia-inducible factor 1α HUVEC, human umbilical vein endothelial cells IEC, ion exchange chromatography IF, intermediate filaments ip, intraperitoneal KO, knockout LPS, lipopolysaccharide MALDI-TOF MS, matrix-assisted laser desorption ionization time of flight mass spectrometry MLEC, mouse lung endothelial cells MMP, matrix metalloproteinase mTOR, mammalian target of rapamycin PAI-1, plasminogen activator inhibitor 1 PI3K, phosphatidylinositol-3 kinase PFS, progression free survival PKC, protein kinase C PLGF, placenta growth factor 9 ROS, reactive oxygen species RTKI, receptor tyrosine kinase inhibitor sc, subcutaneous sCD44, soluble CD44 TGF-α, transforming growth factor α TGF-β , transforming growth factor β ULF, unit-length filament VEGF, vascular endothelial growth factor VEGFR, vascular endothelial growth factor receptor wt, wild type Recombinant CD44-HABD is a novel and potent direct angiogenesis inhibitor enforcing endothelial cell-specific growth inhibition independently of hyaluronic acid binding
Author: Päll, Taavi
Language: Finnish
Subfield: Cell Biology
Open Access status: green
OpenAlex ID: W6987408069
FWCI:
Cites: 262
Cited by:
Related to: 10